Effect of Vitamin D in pregnant wome

Phase 3

Recruiting

• Conditions: Certain conditions originating in the perinatal period.; Other specified conditions originating in the perinatal period; P96.8

• Registration Number: IRCT20190618043927N1
• Lead Sponsor: Shiraz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 October 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 120

Inclusion Criteria

The desire to participate in the study
Do not take vitamin D supplementation routinely
Inadequate levels of vitamin D (serum 25 hydroxyvitamin D 50 to 80 nmol per liter or between 20 and 32 ng / ml)
Lack of any of the diseases: rheumatoid arthritis, thyroid disease, parathyroid disease, liver disease, kidney failure, metabolic bone disease, diabetes mellitus, type 1 diabetes, gestational diabetes, malabsorption, and the use of drugs that affect vitamin D.

Exclusion Criteria

Cancellation of the continuation of the study
Sensitivity to vitamin D tablets
Preterm delivery
Gestational Diabetes
Preeclampsia
Difficult Delivery
Asphyxia

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Fasting sugar - Sugar 2 hours after breakfast. Timepoint: 26 weeks and 36 week pregnancy. Method of measurement: Glucometer Bionime.;Systolic and diastolic pressure. Timepoint: 26 weeks before intervention and 36 week. Method of measurement: Blood pressure system.;Lipid profile. Timepoint: 26 weeks and 36 week of pregnancy. Method of measurement: Kitbiorex.;Anthropometric characteristics (height, weight, round head). Timepoint: after birth. Method of measurement: metric system.;Apgar. Timepoint: after birth. Method of measurement: Apgar system.;2 hpp. Timepoint: 26 weeks and 36 week of pregnancy. Method of measurement: Glucometer Bionime.